Artesunate suppositories work with artemisinin suppositories in severe malaria was conducted in Viet Nam in the early 1990s, and clinical trials of rectal artesunate followed by mefloquine treatment in moderately severe malaria were conducted in the mid-1990s in Thailand. A major placebo-controlled clinical trial published in 2009 found that "if patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate [rectal] suppository at the time of referral substantially reduces the risk of death or permanent disability." Artesunate suppositories Artesunate suppositories are used for the treatment of malaria. Artesunate is an antimalarial water-soluble
Mefloquine events, about 11-17% of travelers are incapacitated to some degree. Mefloquine may cause abnormalities with heart rhythms that are visible on electrocardiograms. Combining mefloquine with other drugs that cause similar effects, such as quinine or quinidine, can increase these effects. Combining mefloquine with halofantrine can cause significant increases in QTc intervals. Mefloquine is contraindicated in those with a previous history of seizures or a recent history of psychiatric disorders. Women should not become pregnant and should use effective birth control while taking mefloquine. A retrospective analysis of outcomes in more than 2,500 women found no evidence that mefloquine was associated